Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe ...
If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Will the cancer return, and if so, ...
While many of the companies currently developing blood tests to help diagnose cancer or track the disease’s progression are churning out physical tests that can be sent out to labs and hospitals ...
Even after a tumor has been removed and a patient is in remission, tiny traces of cancer can still remain in the bloodstream. Without knowing just how many of those cells remain, oncologists may under ...
Veracyte Inc. revealed plans to buy C2i Genomics Inc. at the J.P. Morgan Health Care Conference in San Francisco on Jan. 8, a move that will significantly expand its portfolio of cancer diagnostic and ...
C2i Genomics' scalable software-as-a-service (SaaS) solution analyzes the WGS for high-precision, personalized cancer management to meet existing cancer monitoring shortcomings. The highly ...
Anyone who has had a malignant tumor removed knows the anxiety that follows. Did any traces of cancer remain, and if it returns, will doctors catch it before it’s too late? To reduce the uncertainty ...
NEW YORK--(BUSINESS WIRE)--C2i Genomics (“C2i”), a company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, today ...
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India. Cancer rates in India are an epidemic on the rise; from 2010 to 2019, cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results